Ofatumumab
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Leukaemia, Lymphocytic, Chronic
Conditions
Leukaemia, Lymphocytic, Chronic
Trial Timeline
May 6, 2010 → Jun 26, 2018
NCT ID
NCT01039376About Ofatumumab
Ofatumumab is a phase 3 stage product being developed by Novartis for Leukaemia, Lymphocytic, Chronic. The current trial status is terminated. This product is registered under clinical trial identifier NCT01039376. Target conditions include Leukaemia, Lymphocytic, Chronic.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06345157 | Pre-clinical | Active |
| NCT06167642 | Pre-clinical | Recruiting |
| NCT05199571 | Approved | Completed |
| NCT05171972 | Pre-clinical | Active |
| NCT05084638 | Approved | Completed |
| NCT04869358 | Approved | Completed |
| NCT04486716 | Phase 3 | Completed |
| NCT04353492 | Phase 3 | Completed |
| NCT01848145 | Phase 2 | Completed |
| NCT01039376 | Phase 3 | Terminated |
Competing Products
20 competing products in Leukaemia, Lymphocytic, Chronic